188 related articles for article (PubMed ID: 38693863)
21. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
[TBL] [Abstract][Full Text] [Related]
22. Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines.
Mizumoto A; Yamamoto K; Nakayama Y; Takara K; Nakagawa T; Hirano T; Hirai M
J Pharmacol Exp Ther; 2015 Nov; 355(2):152-8. PubMed ID: 26306766
[TBL] [Abstract][Full Text] [Related]
23. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib.
Zucca LE; Morini Matushita MA; da Silva Oliveira RJ; Scapulatempo-Neto C; de Lima MA; Ribeiro GG; Viana CR; Cárcano FM; Reis RM
Urol Oncol; 2018 Jan; 36(1):11.e13-11.e21. PubMed ID: 28986088
[TBL] [Abstract][Full Text] [Related]
24. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
25. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
26. G-Protein-coupled Estrogen Receptor 1 Agonist G-1 Perturbs Sunitinib Resistance-related Phosphoproteomic Signatures in Renal Cell Carcinoma.
Chen SK; Wang YC; Lin TY; Wu HJ; Huang CJ; Ku WC
Cancer Genomics Proteomics; 2021; 18(3):207-220. PubMed ID: 33893075
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
Jin J; Xie Y; Zhang JS; Wang JQ; Dai SJ; He WF; Li SY; Ashby CR; Chen ZS; He Q
Drug Resist Updat; 2023 Mar; 67():100929. PubMed ID: 36739809
[TBL] [Abstract][Full Text] [Related]
28. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma.
Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM
Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903
[TBL] [Abstract][Full Text] [Related]
30. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
31. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Marona P; Górka J; Kwapisz O; Jura J; Rys J; Hoffman RM; Miekus K
Cell Death Dis; 2022 Sep; 13(9):814. PubMed ID: 36138026
[TBL] [Abstract][Full Text] [Related]
32. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
33. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
[TBL] [Abstract][Full Text] [Related]
34. Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma.
Ruan H; Li S; Bao L; Zhang X
Oncogene; 2020 Sep; 39(38):6113-6128. PubMed ID: 32814829
[TBL] [Abstract][Full Text] [Related]
35. An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines.
Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982721
[TBL] [Abstract][Full Text] [Related]
36. PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.
Bender C; Ullrich A
Int J Cancer; 2012 Jul; 131(2):E45-55. PubMed ID: 22020623
[TBL] [Abstract][Full Text] [Related]
37. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
[TBL] [Abstract][Full Text] [Related]
38. Trichostatin A modulates cellular metabolism in renal cell carcinoma to enhance sunitinib sensitivity.
Sato H; Uzu M; Kashiba T; Fujiwara T; Hatakeyama H; Ueno K; Hisaka A
Eur J Pharmacol; 2019 Mar; 847():143-157. PubMed ID: 30689992
[TBL] [Abstract][Full Text] [Related]
39. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
[TBL] [Abstract][Full Text] [Related]
40. Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells.
Gao H; Deng L
Cell Biochem Biophys; 2014 Mar; 68(2):419-25. PubMed ID: 23975598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]